Ab­b­Vie lines up a new pre­clin­i­cal R&D al­liance with the deal­mak­ers at nat­ur­al killer play­er Drag­on­fly

Bill Haney is build­ing on his rep as one of the most pro­lif­ic deal­mak­ers in pre­clin­i­cal R&D, adding a new al­liance for Drag­on­fly Ther­a­peu­tics with Ab­b­Vie on can­cer drugs as well as au­toim­mune dis­eases — a new field for the up­start de­vel­op­er.

As is gen­er­al­ly the case with Drag­on­fly, hard num­bers are scarce, but Cel­gene, Mer­ck and Ab­b­Vie have front­ed about $200 mil­lion in cash so far, says the CEO, with more than $7 bil­lion in mile­stones. Haney’s oth­er biotech is Sky­hawk, a pop­u­lar play­er in the field of drug­ging RNA, which has grabbed $350 mil­lion to $400 mil­lion in up­front pay­ments and more than $15 bil­lion in mile­stones from a slate of part­ners.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER